Previous study in vitro showed that palbociclib in combination with hormone therapy (tamoxifen) or target therapy (trastuzumab) had an effectively inhibitory effect on ER-positive and HER2-amplified breast cancer, respectively [7]. The gene discussed is ERBB2; the disease is breast cancer.